JLE

Epileptic Disorders

MENU

Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice Volume 20, issue 1, February 2018

Figure 1

Responder rates for total seizures and tonic-atonic seizures in (A) the original Phase III trial and (B) the long-term extension study of the original Phase III trial. Response was defined as ≥50% seizure frequency reduction from baseline. Figure 1A adapted from Glauser et al., 2008 ; figure 1B adapted from Kluger et al., 2010a.

Figure 2

Median percentage change from baseline in 28-day frequency of total and tonic-atonic seizures in a randomised, double-blind, placebo-controlled trial conducted in Japan. Adapted from Ohtsuka et al., 2014.

Figure 3

(A) Median percentage changes from baseline in 28-day frequency and (B) responder rates for all seizures and drop-attack seizures in adult patients with LGS (n=31). Response was defined as ≥50% seizure frequency reduction from baseline. Adapted from McMurray and Striano, 2016.